{"id": "367914", "url": "https://fevir.net/resources/Evidence/367914", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"], "versionId": "26", "lastUpdated": "2025-08-18T13:22:42.074Z"}, "name": "NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG001", "title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367914. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367914. Computable resource at: https://fevir.net/resources/Evidence/367914#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "statistic": [{"quantity": {"unit": "proportion of participants", "value": 0.5769}, "sampleSize": {"knownDataCount": 30}, "statisticType": {"text": "Number (see protocol for details)"}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "367914", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"note": [{"text": "Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol."}, {"text": "Outcome Measure Denominator Units: Participants"}], "observed": {"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.", "identifier": {"type": {"text": "ClinicalTrials.gov Outcome Measurement Group Id"}, "value": "OG001"}}, "description": "Candesartan", "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks (NCT03640312)", "reference": "EvidenceVariable/370507", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-3-12-weeks-", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}